InMode Ltd. (INMD) – What Are Analysts Saying About This Stock?

InMode Ltd. (NASDAQ:INMD) has been assigned an average rating of “Hold” from the five research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $16.00.

Separately, Weiss Ratings cut InMode from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday.

Institutional Investors Weigh In On InMode

A number of large investors have recently made changes to their positions in the company. Inspire Investing LLC lifted its position in shares of InMode by 6.1% during the 1st quarter. Inspire Investing LLC now owns 19,366 shares of the healthcare company’s stock valued at $265,000 after buying an additional 1,111 shares in the last quarter. Plan A Wealth LLC grew its stake in shares of InMode by 8.4% during the 3rd quarter. Plan A Wealth LLC now owns 19,201 shares of the healthcare company’s stock valued at $272,000 after acquiring an additional 1,481 shares during the period. Parallel Advisors LLC increased its holdings in InMode by 43.3% in the 3rd quarter. Parallel Advisors LLC now owns 4,934 shares of the healthcare company’s stock worth $70,000 after acquiring an additional 1,490 shares in the last quarter. Evergreen Capital Management LLC increased its holdings in InMode by 10.8% in the 3rd quarter. Evergreen Capital Management LLC now owns 15,606 shares of the healthcare company’s stock worth $221,000 after acquiring an additional 1,519 shares in the last quarter. Finally, IFP Advisors Inc bought a new stake in InMode during the 2nd quarter worth approximately $31,000. 68.04% of the stock is currently owned by institutional investors.

InMode Stock Performance

Shares of NASDAQ:INMD opened at $13.40 on Friday. InMode has a fifty-two week low of $12.72 and a fifty-two week high of $16.67. The business has a 50-day simple moving average of $14.28 and a two-hundred day simple moving average of $14.32. The firm has a market cap of $770.25 million, a price-to-earnings ratio of 10.89 and a beta of 1.98.

InMode (NASDAQ:INMD) last posted its earnings results on Wednesday, August 5th. The healthcare company reported $0.35 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.35. InMode had a net margin of 20.69% and a return on equity of 11.99%. The business had revenue of $95.59 million for the quarter, compared to analysts’ expectations of $94.89 million. During the same quarter in the prior year, the business earned $0.47 EPS. The business’s revenue for the quarter was up .0% compared to the same quarter last year.

InMode Company Profile

InMode Ltd. (NASDAQ: INMD) is a global medical technology company that develops and commercializes energy-based platforms for aesthetic and medical treatments. Its systems are designed to support minimally invasive and noninvasive procedures performed by physicians and other healthcare professionals.

The company’s product portfolio includes platforms and handpieces used in facial and body contouring, skin resurfacing, skin tightening, hair removal, and women’s health applications. Its technologies include radio-frequency and other energy-based treatments, with products such as Morpheus8, BodyTite, FaceTite, Optimas, and EmpowerRF serving a range of clinical and aesthetic needs.

Founded in 2008, InMode sells its products through direct sales and distribution channels to medical practices, clinics, and other healthcare providers.